

Ryan J Sullivan

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/164789/ryan-j-sullivan-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

287
papers

15,852
citations

59
h-index

123
g-index

317
ext. papers

21,682
ext. citations

8.4
avg, IF

6.53
L-index

#	Paper	IF	Citations
287	Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors.. <i>European Journal of Cancer</i> , 2022 , 163, 108-118	7.5	4
286	Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer.. <i>Cancer Cell</i> , 2022 ,	24.3	5
285	Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma.. <i>Cell Reports Medicine</i> , 2022 , 3, 100500	18	2
284	Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors.. <i>Frontiers in Oncology</i> , 2022 , 12, 818679	5.3	1
283	STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming.. <i>Nature Communications</i> , 2022 , 13, 1859	17.4	1
282	Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy.. <i>Science Advances</i> , 2022 , 8, eabl6339	14.3	2
281	Adoptive Cell Transfer and Vaccines in Melanoma: The Horizon Comes Into View.. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022 , 42, 1-8	7.1	0
280	Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. <i>Cell</i> , 2021 , 184, 6119-6137.e26	56.2	13
279	478 COM701 in combination with BMS-986207 (anti-TIGIT antibody) and nivolumab [preliminary results of safety, tolerability and pharmacokinetics in patients with advanced solid tumors (NCT04570839) 2021 , 9, A508-A508		0
278	IMMU-02. GENOMIC AND TRANSCRIPTOMIC CORRELATES OF IMMUNOTHERAPY RESPONSE WITHIN THE TUMOR MICROENVIRONMENT OF LEPTOMENINGEAL METASTASES. <i>Neuro-Oncology</i> , 2021 , 23, vi92-vi92	1	
277	Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. <i>Journal of Clinical Oncology</i> , 2021 , JCO2101891	2.2	15
276	804 Real-world incidence and impact of pneumonitis in lung cancer patients treated with immune checkpoint inhibitors 2021 , 9, A841-A841		
275	BIOM-04. SENSITIVE DETECTION OF LEPTOMENINGEAL DISEASE USING CELL-FREE DNA FROM CEREBROSPINAL FLUID. <i>Neuro-Oncology</i> , 2021 , 23, vi10-vi10	1	
274	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.. <i>European Journal of Cancer</i> , 2021 , 162, 22-33	7.5	2
273	Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy 2021 , 9,		4
272	Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma. <i>Nature Communications</i> , 2021 , 12, 6023	17.4	1
271	Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. <i>Nature Communications</i> , 2021 , 12, 5954	17.4	7

270	Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases. <i>Nature Communications</i> , 2021 , 12, 5955	17.4	4
269	Immune checkpoint inhibitors for cancer and venous thromboembolic events. <i>European Journal of Cancer</i> , 2021 , 158, 99-110	7.5	7
268	Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. <i>Oncologist</i> , 2021 , 26, 514-522	5.7	6
267	Electrocardiographic features of immune checkpoint inhibitor associated myocarditis 2021 , 9,		10
266	Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1503-1516	15.1	28
265	The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020. <i>Journal of Translational Medicine</i> , 2021 , 19, 144	8.5	
264	Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations.. <i>Nature Cancer</i> , 2021 , 2, 498-502	15.4	9
263	Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. <i>Cancer Discovery</i> , 2021 , 11, 2488-2505	24.4	11
262	Clinical Cancer Advances 2021: ASCO® Report on Progress Against Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1165-1184	2.2	16
261	Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study 2021 , 9,		10
260	The use of cryoablation to overcome resistance to PD-1 blockade in unresectable melanoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9538-9538	2.2	
259	COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies (NCT03667716).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2504-2504	2.2	2
258	Improving patient and caregiver understanding of risks and benefits of immunotherapy for melanoma or lung cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS6596-TPS6596	2.2	
257	Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study. <i>Oncologist</i> , 2021 , 26, 731-e1498	5.7	3
256	Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. <i>JAMA Oncology</i> , 2021 , 7, 744-748	13.4	25
255	Advanced imaging to assess longitudinal vascular changes in brain metastases treated with checkpoint inhibition.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3059-3059	2.2	
254	Overall survival benefit from tebentafusp in patients with best response of progressive disease.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9509-9509	2.2	2
253	Temporal Trends in Inpatient Oncology Census Before and During the COVID-19 Pandemic and Rates of Nosocomial COVID-19 Among Patients with Cancer at a Large Academic Center. <i>Oncologist</i> , 2021 , 26, e1427-e1433	5.7	3

252	Characterizing the tumor and immune landscape of melanoma patients treated with combined checkpoint blockade and MAPK targeted therapy.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9522-9522	2.2	
251	Knowledge about risks, benefits, and curative potential of immunotherapy among patients with advanced lung cancer or melanoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 6579-6579	2.2	
250	Evolution of delayed resistance to immunotherapy in a melanoma responder. <i>Nature Medicine</i> , 2021 , 27, 985-992	50.5	11
249	Impact of multidisciplinary severe immunotherapy complication service on outcomes for cancer patients receiving immune checkpoint inhibition.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2654-2654	2.2	
248	Discrepancies in response and immune-related adverse events (irAE) of anti-PD-1 monotherapy between races and primary sites in patients (pts) with advanced nonacral cutaneous melanoma (NACM).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9530-9530	2.2	0
247	Safety, pharmacokinetic and pharmacodynamic results from dose escalation of SAR439459, a TGFβ inhibitor, as monotherapy or in combination with cemiplimab in a phase 1/1b study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2510-2510	2.2	0
246	Secondary histiocytic sarcoma with BRAF mutation responsive to MAPK-targeted therapy presenting with recurrence with mTOR mutation responsive to mTOR-targeted therapy. <i>Pediatric Blood and Cancer</i> , 2021 , 68, e29166	3	0
245	Rejection of benign melanocytic nevi by nevus-resident CD4 T cells. <i>Science Advances</i> , 2021 , 7,	14.3	1
244	Pericardial disease in patients treated with immune checkpoint inhibitors 2021 , 9,		2
243	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors 2021 , 9,		20
242	Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. <i>Nature Reviews Drug Discovery</i> , 2021 ,	64.1	26
241	Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting. <i>Oncologist</i> , 2021 , 26, 49-55	5.7	9
240	Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. <i>British Journal of Cancer</i> , 2021 , 124, 574-580	8.7	9
239	Emerging Immunotherapies in the Treatment of Brain Metastases. <i>Oncologist</i> , 2021 , 26, 231-241	5.7	12
238	Liver biopsy findings in patients on immune checkpoint inhibitors. <i>Modern Pathology</i> , 2021 , 34, 426-437	9.8	15
237	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition 2021 , 9,		20
236	The State of Melanoma: Emergent Challenges and Opportunities. <i>Clinical Cancer Research</i> , 2021 , 27, 2678-2697	12.9	11
235	Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors. <i>Immunotherapy Advances</i> , 2021 , 1, ltab014		2

234	Thermal Ablation, Embolization, and Selective Internal Radiation Therapy Combined with Checkpoint Inhibitor Cancer Immunotherapy: Safety Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2021 , 32, 187-195	2.4	4
233	Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort 2021 , 9,		1
232	Abstract CT002: Phase 3 randomized trial comparing tebentafusp with investigator's choice in first line metastatic uveal melanoma 2021 ,		5
231	Early Use of High-Dose Glucocorticoid for the Management of irAEs Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy. <i>Clinical Cancer Research</i> , 2021 , 27, 5993-6000	12.9	11
230	Detection of Leptomeningeal Disease Using Cell-Free DNA From Cerebrospinal Fluid. <i>JAMA Network Open</i> , 2021 , 4, e2120040	10.4	6
229	Knowledge About Risks, Benefits, and Curative Potential of Immunotherapy Among Patients with Advanced Cancer. <i>Oncologist</i> , 2021 , 26, e2090-e2093	5.7	0
228	Long-term Overall Survival and Predictors in Anti-PD-1-naïve Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study. <i>Journal of Immunotherapy</i> , 2021 , 44, 307-318	5	1
227	Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer 2021 , 9,		1
226	Absolute quantification of tumor antigens using embedded MHC-I isotopologue calibrants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	3
225	Real-world assessment of response to anti-programmed cell death 1 therapy in advanced cutaneous squamous cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, 1038-1040	4.5	5
224	A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. <i>Onc Immunology</i> , 2021 , 10, 1875639	7.2	8
223	CTIM-02. PHASE II STUDY OF IPILIMUMAB AND NIVOLUMAB IN LEPTOMENINGEAL CARCINOMATOSIS. <i>Neuro-Oncology</i> , 2021 , 23, vi49-vi49	1	
222	Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. <i>Nature Medicine</i> , 2020 , 26, 1280-1284	50.5	34
221	COVID-19 and immune checkpoint inhibitors: initial considerations 2020 , 8,		36
220	Acute Kidney Injury Following Encorafenib and Binimetinib for Metastatic Melanoma. <i>Kidney Medicine</i> , 2020 , 2, 373-375	2.8	3
219	Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Circulation</i> , 2020 , 141, 2031-2034	16.7	60
218	Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis 2020 , 8,		15
217	Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. <i>Cancer</i> , 2020 , 126, 3758-3767	6.4	10

216	Case 9-2020: A 64-Year-Old Man with Shortness of Breath, Cough, and Hypoxemia. <i>New England Journal of Medicine</i> , 2020 , 382, 1150-1159	59.2	3
215	Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. <i>Cell</i> , 2020 , 182, 655-671.	52.2	85
214	Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study 2020 , 8,		28
213	When is it OK to Stop Anti-Programmed Death 1 Receptor (PD-1) Therapy in Metastatic Melanoma?. <i>American Journal of Clinical Dermatology</i> , 2020 , 21, 313-321	7.1	2
212	Secondary histiocytic sarcoma with BRAF mutation after T-cell acute lymphoblastic leukemia in a very young child with dramatic response to dabrafenib and trametinib. <i>Pediatric Blood and Cancer</i> , 2020 , 67, e28200	3	7
211	Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum. <i>Annals of Neurology</i> , 2020 , 87, 659-669	9.4	67
210	Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. <i>European Heart Journal</i> , 2020 , 41, 1733-1743	9.5	114
209	The potential of BRAF-targeted therapy combined with immunotherapy in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 131-136	3.5	5
208	Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 467-478	15.1	87
207	Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce 2020 , 8,		43
206	IMMU-01. SINGLE CELL SEQUENCING OF MELANOMA BRAIN METASTASES UNVEILS HETEROGENEITY OF THE TUMOR MICROENVIRONMENT IN RESPONSE TO IMMUNE CHECKPOINT BLOCKADE. <i>Neuro-Oncology</i> , 2020 , 22, ii104-ii104	1	0
205	NIMG-05. ADVANCED IMAGING TO ASSESS LONGITUDINAL VASCULAR CHANGES IN BRAIN METASTASES TREATED WITH CHECKPOINT INHIBITION. <i>Neuro-Oncology</i> , 2020 , 22, ii147-ii147	1	
204	285 Phase I clinical trial evaluating the safety of ADP-A2M10 in patients with MAGE-A10+ head and neck, melanoma, or urothelial tumors 2020 , 8, A311-A311		1
203	352 Updated clinical data from the squamous cell carcinoma of the head and neck (SCCHN) expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab 2020 , 8, A377-A377		3
202	434 Updated clinical data from the melanoma expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab 2020 , 8, A460-A460		2
201	Heterogeneous response and irAE patterns in advanced melanoma patients treated with anti-PD-1 monotherapy from different ethnic groups: Subtype distribution discrepancy and beyond.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10020-10020	2.2	2
200	A phase II study of ERK inhibition by ulixertinib (BVD-523) in metastatic uveal melanoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10036-10036	2.2	6
199	A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36 for intratumoral (iTU) injection alone and in combination with durvalumab.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3092-3092	2.2	19

198	Association of vitamin D intake with decreased risk of immune checkpoint inhibitor-induced colitis.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 89-89	2.2	3
197	A phase I study evaluating COM701 monotherapy and in combination with nivolumab in patients with advanced solid malignancies.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS23-TPS23	2.2	1
196	CTEP 9557: A dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF mutant solid tumors.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3609-3609	2.2	0
195	Investigating the tumor immune infiltrate for populations that predict immune-related adverse events (irAEs) in patients receiving PD-1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3116-3116	2.2	
194	The use of plasma proteomic markers to understand the biology of immunotherapy response.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10062-10062	2.2	
193	Advanced imaging to assess longitudinal vascular changes in brain metastases treated with immune checkpoint inhibition.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2529-2529	2.2	
192	Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib. <i>Nephrology Dialysis Transplantation</i> , 2020 ,	4.3	4
191	A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 460-467	6.1	28
190	Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. <i>Circulation</i> , 2020 , 142, 2299-2311	16.7	85
189	A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with -mutant Solid Tumors. <i>Clinical Cancer Research</i> , 2020 , 26, 5102-5112	12.9	7
188	Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome. <i>Science Advances</i> , 2020 , 6,	14.3	14
187	Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Journal of the American Heart Association</i> , 2020 , 9, e018306 ⁶		12
186	Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. <i>Lancet Oncology, The</i> , 2020 , 21, e398-e404	21.7	35
185	Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors. <i>Kidney International Reports</i> , 2020 , 5, 1700-1705	4.1	13
184	Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma. <i>Clinical Cancer Research</i> , 2020 , 26, 6039-6050	12.9	9
183	Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. <i>Neurology</i> , 2019 , 93, e1093-e1103	6.5	72
182	Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. <i>Nature Medicine</i> , 2019 , 25, 929-935	50.5	124
181	Back to the Future: Rethinking and Retooling IL2 in the Immune Checkpoint Inhibitor Era. <i>Cancer Discovery</i> , 2019 , 9, 694-695	24.4	6

180	The metastatic dissemination of a squamous cell carcinoma arising from an epidermal cyst and subsequent failure to respond to programmed death 1 inhibition. <i>JAAD Case Reports</i> , 2019 , 5, 375-378	1.4	
179	Frontline Therapy for -Mutated Metastatic Melanoma: How Do You Choose, and Is There One Correct Answer?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019 , 39, 564-571	7.1	29
178	Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma. <i>Clinical Cancer Research</i> , 2019 , 25, 5735-5742	12.9	17
177	Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 897-905	7.4	21
176	Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors 2019 , 7, 53		42
175	PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1CD38 cells and anti-PD-1 resistance. <i>Nature Immunology</i> , 2019 , 20, 1231-1243	19.1	132
174	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology, The</i> , 2019 , 20, e378-e389	21.7	88
173	A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of -mutated Melanoma to MAPK Inhibitors. <i>Clinical Cancer Research</i> , 2019 , 25, 6852-6867	12.9	33
172	The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019 , 14, 1692-1700	6.9	95
171	Budesonide treatment for microscopic colitis from immune checkpoint inhibitors 2019 , 7, 292		27
170	A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3001-3001	2.2	14
169	Predictable early onset high-dose-glucocorticoid-associated-irAE and its predictive role in anti-PD-1 monotherapy treated advanced melanoma patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9544-9544	2.2	1
168	A phase II study of cryoablation (cryo) of an enlarging tumor in patients (pts) with advanced lung cancer or melanoma receiving post-progression immune checkpoint inhibition (ICI).. <i>Journal of Clinical Oncology</i> , 2019 , 37, e14243-e14243	2.2	1
167	Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. <i>European Journal of Endocrinology</i> , 2019 , 181, 211-219	6.5	61
166	Liquid biopsy using plasma proteomic profiling to reveal predictors of immunotherapy response.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 130-130	2.2	0
165	Prognostic models for advanced melanoma patients treated with anti-PD-1 monotherapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 133-133	2.2	
164	A phase I study evaluating COM701 in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS2657-TPS2657	2.2	
163	Clinical features and response to immune checkpoint inhibitors (ICIs) in pregnancy-associated melanoma (PAM).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9564-9564	2.2	

162	Clinical outcomes of patients with stage IV cancer receiving immune checkpoint inhibitors in the inpatient setting.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 6634-6634	2.2	1
161	Organ site-specific radiological responses in anti-PD-1 monotherapy treated advanced melanoma patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9552-9552	2.2	
160	Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control. <i>Oncologist</i> , 2019 , 24, 671-679	5.7	19
159	Anti-PD-1-Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients. <i>Cancer Immunology Research</i> , 2019 , 7, 1755-1759	12.5	11
158	Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study. <i>Melanoma Research</i> , 2019 , 29, 65-69	3.3	19
157	CMET-33. PHASE II STUDY OF PALBOCICLIB IN BRAIN METASTASES HARBORING CDK PATHWAY ALTERATIONS. <i>Neuro-Oncology</i> , 2019 , 21, vi58-vi59	1	78
156	Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 1127-1132	5.3	38
155	Clinical characterization of colitis arising from anti-PD-1 based therapy. <i>OncolImmunology</i> , 2019 , 8, e1524695	6.5	25
154	Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy. <i>Cancer</i> , 2019 , 125, 884-891	6.4	30
153	Mechanisms of Resistance to Immune Checkpoint Blockade. <i>American Journal of Clinical Dermatology</i> , 2019 , 20, 41-54	7.1	51
152	Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 81, 1129-1141	3.5	15
151	Management of Metastatic Melanoma in 2018. <i>JAMA Oncology</i> , 2018 , 4, 857-858	13.4	22
150	Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. <i>EMBO Molecular Medicine</i> , 2018 , 10,	12	42
149	Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 2467-2472	11.5	82
148	Circulating BRAF Levels Correlate with Treatment in Patients with Thyroid Carcinoma. <i>Thyroid</i> , 2018 , 28, 328-339	6.2	15
147	A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. <i>OncolImmunology</i> , 2018 , 7, e1423172	7.2	20
146	Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. <i>European Journal of Cancer</i> , 2018 , 91, 116-124	7.5	54
145	First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. <i>Cancer Discovery</i> , 2018 , 8, 184-195	24.4	198

144	The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017. <i>Journal of Translational Medicine</i> , 2018 , 16, 101	8.5	3
143	Dual MAPK/CDK Targeting in Melanoma: New Approaches, New Challenges. <i>Cancer Discovery</i> , 2018 , 8, 532-533	24.4	8
142	Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1755-1764	15.1	572
141	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0 2018 , 6, 44		39
140	Forestalling BRAF-Inhibitor Resistance in a Shocking Way. <i>Clinical Cancer Research</i> , 2018 , 24, 5496-5498	12.9	1
139	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy) 2018 , 6, 69		10
138	Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. <i>Nature Medicine</i> , 2018 , 24, 1545-1549	50.5	230
137	Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. <i>JCI Insight</i> , 2018 , 3,	9.9	67
136	Phase II study of pembrolizumab in leptomeningeal carcinomatosis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2007-2007	2.2	16
135	Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3013-3013	2.2	36
134	Initial safety assessment of MAGE-A10c796TCR T-cells in two clinical trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3056-3056	2.2	6
133	Cost of inpatient admissions for immune-related adverse effects from immune checkpoint inhibitor therapy: A single center experience.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3060-3060	2.2	2
132	Autoimmune genetic variants as germline biomarkers of response in melanoma immunotherapy treatment.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3079-3079	2.2	2
131	Characterization of immune related hepatitis (irH) from immune checkpoint inhibitors (ICIs).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3087-3087	2.2	2
130	Severe immune-related adverse effects (irAE) requiring hospital admission in patients treated with immune checkpoint inhibitors for advanced malignancy: Temporal trends and clinical significance.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3096-3096	2.2	3
129	Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma progressing on or after a PD-1/L1 blocking antibody.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9530-9530	2.2	14
128	Analysis of the kinetics and effects of vemurafenib (V) + cobimetinib (C) on intratumoral and host immunity in patients (pts) with BRAFV600 mutant melanoma (BRAFM): Implications for combination with immunotherapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9559-9559	2.2	3
127	Immune checkpoint inhibition (ICI) in advanced cutaneous squamous cell carcinoma (cSCC): Clinical response and correlative biomarker analysis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9564-9564	2.2	5

126	Inpatient admissions related to immune-related adverse effects (irAE) among patients treated with immune checkpoint inhibitors for advanced malignancy: A tsunami is coming, but are we ready?. <i>Journal of Clinical Oncology</i> , 2018 , 36, 127-127	2.2	7
125	The role of targeted therapy for melanoma in the immunotherapy era. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2018 , 37, 112-119	1.4	2
124	Predictive plasma proteomic biomarkers of immunotherapy toxicity in patients (pts) with metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e21569-e21569	2.2	1
123	Phylogenetic analysis of longitudinal melanoma samples to reveal convergent evolution and markers of immunotherapy resistance.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9581-9581	2.2	
122	Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who have received PD-1 based therapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9540-9540	2.2	2
121	Association of anti-PD-1 (PD1) induced pneumonitis with persistent imaging and lung function abnormalities in some patients.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e15147-e15147	2.2	
120	A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2018 , 6, 79-86	12.5	46
119	Keeping Expectations in Check With Immune Checkpoint Inhibitors. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1654-1657	2.2	32
118	CMET-20. EVIDENCE OF CNS RESPONSE OF PEMBROLIZUMAB FOR LEPTOMENINGEAL CARCINOMATOSIS AT A SINGLE CELL RESOLUTION. <i>Neuro-Oncology</i> , 2018 , 20, vi57-vi58	1	1
117	GENE-18. DIVERGENT CLONAL EVOLUTION OF MELANOMA BRAIN METASTASES DURING TREATMENT WITH IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2018 , 20, vi106-vi107	1	78
116	CMET-16. THE ROLE OF SURGICAL RESECTION OF MELANOMA BRAIN METASTASES IN THE IMMUNOTHERAPY ERA. <i>Neuro-Oncology</i> , 2018 , 20, vi56-vi57	1	78
115	NIMG-63. ADVANCED IMAGING FOR ASSESSING VOLUMETRIC RESPONSES IN BRAIN METASTASES TREATED WITH CHECKPOINT BLOCKADE. <i>Neuro-Oncology</i> , 2018 , 20, vi190-vi190	1	78
114	Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. <i>Melanoma Research</i> , 2018 , 28, 605-610	3.3	18
113	Reply to emergency management of immune-related hypophysitis: Collaboration between specialists is essential to achieve optimal outcomes. <i>Cancer</i> , 2018 , 124, 4732	6.4	1
112	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. <i>Cell</i> , 2018 , 175, 984-997.e24	56.2	477
111	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. <i>Cell</i> , 2018 , 175, 998-1013.e20	56.2	631
110	Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , 2018 , 4, 1721-1728	13.4	893
109	Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action. <i>Oncologist</i> , 2018 , 23, 874-878	5.7	64

108	High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. <i>Cancer</i> , 2018 , 124, 3706-3714	6.4	213
107	Point of care assessment of melanoma tumor signaling and metastatic burden from NMR analysis of tumor fine needle aspirates and peripheral blood. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017 , 13, 821-828	6	6
106	Immune checkpoint inhibitors in challenging populations. <i>Cancer</i> , 2017 , 123, 1904-1911	6.4	194
105	Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 623-629	12.9	61
104	Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic -Mutant Melanoma. <i>Clinical Cancer Research</i> , 2017 , 23, 5339-5348	12.9	101
103	Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma. <i>Oncologist</i> , 2017 , 22, 963-971	9.7	96
102	Resistance to checkpoint blockade therapy through inactivation of antigen presentation. <i>Nature Communications</i> , 2017 , 8, 1136	17.4	409
101	PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. <i>Nature</i> , 2017 , 550, 133-136	50.4	100
100	Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors. <i>JCO Precision Oncology</i> , 2017 , 2017,	3.6	28
99	CMET-16. THE ROLE OF SURGICAL RESECTION OF MELANOMA BRAIN METASTASES IN THE IMMUNOTHERAPY ERA. <i>Neuro-Oncology</i> , 2017 , 19, vi42-vi42	1	78
98	Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings. <i>Radiographics</i> , 2017 , 37, 2132-2144	5.4	68
97	A first-in-human dose phase 1 study of LY3009120 in advanced cancer patients.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2507-2507	2.2	6
96	First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2508-2508	2.2	11
95	Phase 1 study of the p53-MDM2 inhibitor AMG 232 combined with trametinib plus dabrafenib or trametinib in patients (Pts) with TP53 wild type (TP53WT) metastatic cutaneous melanoma (MCM).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2575-2575	2.2	10
94	Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3063-3063	2.2	36
93	A phase Ib study of napabucasin plus weekly paclitaxel in patients with advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9553-9553	2.2	3
92	Inflammatory arthritis: An under-recognized immune-relate adverse effect.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e14565-e14565	2.2	1
91	Neurotoxicity associated with anti-PD1 therapy: A multi-center case series.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e21641-e21641	2.2	3

90	A phase I single arm, open label clinical trial evaluating safety of MAGE-A10c796T in subjects with advanced or metastatic head and neck, melanoma, or urothelial tumors (NCT02989064).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS3098-TPS3098	2.2	3
89	Mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 35-35	2.2	1
88	ASN003, a highly selective BRAF and PI3K inhibitor: Preclinical and phase 1 clinical data in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e14102-e14102	2.2	
87	Expression quantitative trait loci (eQTLs) as germline determinants of melanoma immunotherapy response.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3017-3017	2.2	
86	Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. <i>Cancer</i> , 2016 , 122, 3344-3353	6.4	199
85	The efficacy of anti-PD-1 agents in acral and mucosal melanoma. <i>Cancer</i> , 2016 , 122, 3354-3362	6.4	164
84	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. <i>Nature Communications</i> , 2016 , 7, 10582	17.4	248
83	Cardiogenic Shock and Respiratory Failure in a Patient With Metastatic Melanoma Receiving Trametinib Therapy. <i>Oncologist</i> , 2016 , 21, 1136-7	5.7	3
82	A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma 2016 , 4, 52		29
81	Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , 2016 , 17, 943-955	21.7	236
80	Primary genitourinary melanoma: Epidemiology and disease-specific survival in a large population-based cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 166.e7-14	2.8	29
79	The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy. <i>American Journal of Clinical Dermatology</i> , 2016 , 17, 1-10	7.1	7
78	Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. <i>JAMA Oncology</i> , 2016 , 2, 234-40	13.4	408
77	Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma. <i>Journal of Molecular Diagnostics</i> , 2016 , 18, 100-8	5.1	24
76	Melanoma driver mutations and immune therapy. <i>Oncolmmunology</i> , 2016 , 5, e1051299	7.2	8
75	Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance. <i>Cancer Discovery</i> , 2016 , 6, 382-99	24.4	113
74	New Translational Research in the Medical Management of Orbital Melanoma. <i>Seminars in Ophthalmology</i> , 2016 , 31, 53-8	2.4	2
73	mutant melanoma: an overview for the clinician for melanoma management. <i>Melanoma Management</i> , 2016 , 3, 47-59	2.1	10

72	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. <i>OncImmunology</i> , 2016 , 5, e1136044	7.2	42
71	Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	144
70	Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 105-105	2.2	9
69	Retrospective analysis of activity of pembrolizumab (pembro) in melanoma patients (pts) with brain metastasis (BM).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2071-2071	2.2	0
68	Association of plasma exosomal mRNA changes with long-term durable response to ipilimumab (IPI) in metastatic melanoma (MM) patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3037-3037	2.2	2
67	Pseudoprogression in cancer immunotherapy: Rates, time course and patient outcomes.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6580-6580	2.2	48
66	Efficacy and safety of programmed death receptor-1 (PD-1) blockade in metastatic uveal melanoma (UM).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9507-9507	2.2	5
65	Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders (AD) or major toxicity with ipilimumab (IPI).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9515-9515	2.2	10
64	Clinical activity of anti-programmed death-1 (PD-1) agents in acral and mucosal melanoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9516-9516	2.2	1
63	Survival outcomes of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9517-9517	2.2	1
62	IPI-549-01-A phase 1/1b first in human study of IPI-549, a PI3K- α inhibitor, as monotherapy and in combination with pembrolizumab in subjects with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS3111-TPS3111	2.2	3
61	Functional characterization of non-V600 BRAF mutations and their response to Trametinib (Tram).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9537-9537	2.2	
60	The role of mitogen-activated protein targeting in melanoma beyond BRAFV600. <i>Current Opinion in Oncology</i> , 2016 , 28, 185-91	4.2	13
59	Serum lactate dehydrogenase is a more useful biomarker of prognosis than serum S100B in patients with BRAF-mutant melanoma. <i>British Journal of Dermatology</i> , 2016 , 174, 716-7	4	2
58	EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. <i>Clinical Cancer Research</i> , 2016 , 22, 4585-93	12.9	655
57	Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. <i>Science</i> , 2016 , 352, 189-96	33.3	1961
56	Clusters of circulating tumor cells traverse capillary-sized vessels. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 4947-52	11.5	274
55	Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. <i>JAMA Oncology</i> , 2016 , 2, 1056-64	12.4	34

54	Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. <i>Cancer Immunology Research</i> , 2016 , 4, 959-967	12.5	318
53	Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. <i>Nature Medicine</i> , 2016 , 22, 1056-61	50.5	49
52	Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. <i>Clinical Cancer Research</i> , 2015 , 21, 2289-96	12.9	90
51	Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. <i>Cancer Immunology Research</i> , 2015 , 3, 288-295	12.5	111
50	Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. <i>Seminars in Oncology</i> , 2015 , 42, 601-16	5.5	83
49	Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma. <i>Clinical Cancer Research</i> , 2015 , 21, 2892-7	12.9	27
48	A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma. <i>Oncologist</i> , 2015 , 20, 617-8	5.7	8
47	Rapid Intraoperative Molecular Characterization of Glioma. <i>JAMA Oncology</i> , 2015 , 1, 662-7	13.4	53
46	Achievements and challenges of molecular targeted therapy in melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015 , 177-86	7.1	29
45	New strategies in melanoma: entering the era of combinatorial therapy. <i>Clinical Cancer Research</i> , 2015 , 21, 2424-35	12.9	27
44	BMET-04LEPTOMENINGEAL CARCINOMATOSIS IN MELANOMA. <i>Neuro-Oncology</i> , 2015 , 17, v45.4-v45	1	78
43	Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2506 ^{2,2} -2506 ¹⁰		
42	A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9007-9007	2.2	37
41	Plasma-based monitoring of BRAF mutations during therapy for malignant melanoma (MM) using combined exosomal RNA and cell-free DNA analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9017-9017	2.2	5
40	Phase II study of dabrafenib and trametinib following progression on BRAF inhibitor monotherapy in metastatic melanoma: Exploration of clinical and molecular predictors of response.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20051-e20051	2.2	1
39	A phase II study of combined therapy with vemurafenib (vem) and high-dose interleukin-2 (aldesleukin; HD IL-2) in patients with metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e2007 ^{2,2} -e2007 ¹		
38	Profiling exosomal mRNAs in patients undergoing immunotherapy for malignant melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e22159-e22159	2.2	4
37	Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma. <i>Oncotarget</i> , 2015 , 6, 40535-56	3.3	38

36	Palliative care and hospice use among melanoma patients treated with immunotherapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 116-116	2.2	
35	Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. <i>Cancer</i> , 2014 , 120, 1695-701	6.4	151
34	Assaying for BRAF V600E in tissue and blood in melanoma. <i>Methods in Molecular Biology</i> , 2014 , 1102, 117-36	1.4	5
33	Isolation and molecular characterization of circulating melanoma cells. <i>Cell Reports</i> , 2014 , 7, 645-53	10.6	81
32	Understanding the biology of melanoma and therapeutic implications. <i>Hematology/Oncology Clinics of North America</i> , 2014 , 28, 437-53	3.1	27
31	Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 4078-85	5.6	280
30	Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 3210-8	6.1	20
29	Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. <i>PLoS ONE</i> , 2014 , 9, e101286	3.7	35
28	MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. <i>Cancer Discovery</i> , 2014 , 4, 61-8	24.4	351
27	Phase I-II study of the combination vemurafenib plus peg-interferon in advanced melanoma patients harboring the V600BRAF mutation.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS9105-TPS9105	2.2	
26	Emerging clinical issues in melanoma in the molecularly targeted era. <i>Methods in Molecular Biology</i> , 2014 , 1102, 11-26	1.4	
25	Case records of the Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma. <i>New England Journal of Medicine</i> , 2013 , 369, 173-83	59.2	27
24	BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. <i>Clinical Cancer Research</i> , 2013 , 19, 1225-31	12.9	679
23	Resistance to BRAF-targeted therapy in melanoma. <i>European Journal of Cancer</i> , 2013 , 49, 1297-304	7.5	273
22	The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. <i>Clinical Cancer Research</i> , 2013 , 19, 5283-91	12.9	45
21	BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. <i>Oncolmmunology</i> , 2013 , 2, e26615	7.2	82
20	Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9010-9010	2.2	97
19	Whole exome and whole transcriptome sequencing in melanoma patients to identify mechanisms of resistance to combined RAF/MEK inhibition.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9015-9015	2.2	3

18	NRAS mutation: A potential biomarker of clinical response to immune-based therapies in metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9019-9019	2.2	9
17	Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9028-9028	2.2	24
16	Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9029-9029	2.2	23
15	A phase I study of the combination of sorafenib (Sor) and bortezomib (Bor) in patients (pts) with metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9076-9076	2.2	2
14	Survival patterns following brain metastases for patients with melanoma in the targeted therapy era.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9064-9064	2.2	
13	Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. <i>Journal of Immunotherapy</i> , 2012 , 35, 66-72	5	99
12	Predicting early relapse in patients with BRAFV600E melanoma with a highly sensitive blood BRAF assay.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8516-8516	2.2	1
11	Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8569-8569	2.2	17
10	BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance. <i>Journal of Skin Cancer</i> , 2011 , 2011, 423239	1.4	28
9	Cytokine therapy in melanoma. <i>Journal of Cutaneous Pathology</i> , 2010 , 37 Suppl 1, 60-7	1.7	9
8	Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 1205-16	5.9	13
7	New drug targets in Kaposi sarcoma. <i>Expert Opinion on Therapeutic Targets</i> , 2010 , 14, 1355-66	6.4	13
6	Studying Rac1-induced tumorigenesis suggests antioxidants may help prevent and treat KaposiB sarcoma. <i>Future Oncology</i> , 2009 , 5, 949-52	3.6	
5	Molecular-targeted therapy in malignant melanoma. <i>Expert Review of Anticancer Therapy</i> , 2009 , 9, 567-81.5	3.5	11
4	Targeted therapy for Kaposi sarcoma. <i>BioDrugs</i> , 2009 , 23, 69-75	7.9	27
3	HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. <i>Clinical Infectious Diseases</i> , 2008 , 47, 1209-15	11.6	129
2	Signal transduction targets in KaposiB sarcoma. <i>Current Opinion in Oncology</i> , 2006 , 18, 456-62	4.2	23
1	Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma		1

